Cargando…

Moyamoya Biomarkers

Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recen...

Descripción completa

Detalles Bibliográficos
Autor principal: Smith, Edward R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Neurosurgical Society 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502237/
https://www.ncbi.nlm.nih.gov/pubmed/26180608
http://dx.doi.org/10.3340/jkns.2015.57.6.415
_version_ 1782381169852022784
author Smith, Edward R.
author_facet Smith, Edward R.
author_sort Smith, Edward R.
collection PubMed
description Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recent progress in the development of moyamoya-related biomarkers has stimulated marked interest in this field. Biomarkers can be defined as biologically derived agents-such as specific molecules or unique patterns on imaging-that can identify the presence of disease or help to predict its course. This article reviews the current categories of biomarkers relevant to MMD-including proteins, cells and genes-along with potential limitations and applications for their use.
format Online
Article
Text
id pubmed-4502237
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Neurosurgical Society
record_format MEDLINE/PubMed
spelling pubmed-45022372015-07-15 Moyamoya Biomarkers Smith, Edward R. J Korean Neurosurg Soc Pediatric Issue Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recent progress in the development of moyamoya-related biomarkers has stimulated marked interest in this field. Biomarkers can be defined as biologically derived agents-such as specific molecules or unique patterns on imaging-that can identify the presence of disease or help to predict its course. This article reviews the current categories of biomarkers relevant to MMD-including proteins, cells and genes-along with potential limitations and applications for their use. The Korean Neurosurgical Society 2015-06 2015-06-30 /pmc/articles/PMC4502237/ /pubmed/26180608 http://dx.doi.org/10.3340/jkns.2015.57.6.415 Text en Copyright © 2015 The Korean Neurosurgical Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pediatric Issue
Smith, Edward R.
Moyamoya Biomarkers
title Moyamoya Biomarkers
title_full Moyamoya Biomarkers
title_fullStr Moyamoya Biomarkers
title_full_unstemmed Moyamoya Biomarkers
title_short Moyamoya Biomarkers
title_sort moyamoya biomarkers
topic Pediatric Issue
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502237/
https://www.ncbi.nlm.nih.gov/pubmed/26180608
http://dx.doi.org/10.3340/jkns.2015.57.6.415
work_keys_str_mv AT smithedwardr moyamoyabiomarkers